二甲双胍联合利格列汀治疗肥胖2型糖尿病患者的临床观察

Clinical observation of metformin combined with linagliptin in the treatment of obese patients with type 2 diabetes

目的:探讨二甲双胍联合利格列汀治疗肥胖2型糖尿病的临床效果。方法:将2016年1月-2019年1月60例初发肥胖2型糖尿病患者分为对照组和观察组,每组30例。对照组用二甲双胍治疗,观察组用二甲双胍+利格列汀治疗。观察两组治疗前后血糖、血脂、体质量指数(BMI)及胰岛素抵抗情况。结果:两组治疗6个月后空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素抵抗指数、体质量指数、总胆固醇、甘油三酯、低密度脂蛋白胆固醇均明显低于治疗前,差异有统计学意义(P<0.05)。观察组治疗后上述各指标均明显低于对照组同期,差异有统计学意义(P<0.05)。结论:二甲双胍联合利格列汀能有效降低2型糖尿病合并肥胖患者的血糖、血脂、BMI,改善胰岛素抵抗。

Objective:To investigate the clinical effect of metformin combined with liglitine in the treatment of type 2 diabetes mellitus with obesity.Methods:All 60 cases of newly obese patients with type 2 diabetes were reviewed in department,divided into control group and observation group,30 cases each.The control group was treated with metformin,while the observation group was treated with metformin plus liglitine.The blood glucose,blood lipid,body mass index(BMI)and insulin resistance of the two groups before and after treatment were observed.Results:Fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin,insulin resistance index,body mass index,total cholesterol,triglyceride and low density lipoprotein cholestone were significantly lower in both groups after 6 months of treatment,there was significient difference(P<0.05).After treatment,the above indexes in the observation group were significantly lower than those in the control group,there was significient difference(P<0.05).Conclusion:Metformin combined with ligretin can effectively reduce the blood glucose,blood lipid and BMI of patients with type 2 diabetes complicated with obesity,and improve insulin resistance.